Nir Gilad stepping down as ICL chairman

Nir Gilad

In his role as CEO of Israel Corporation, Gilad became a symbol of excessive executive pay. 

An era is coming to an end at Israel Corporation (TASE: ILCO): Nir Gilad, chairman of subsidiary Israel Chemicals (TASE: ICL: NYSE: ICL) since January 2008, is stepping down. Until 2015, Gilad was also CEO of Israel Corporation.

Sources close to Israel Chemicals confirmed that after a decade of varied and challenging activity, a series of talks had been held with Gilad on an orderly transfer of his job which will take place over the next few months and will be completed by the end of the year.

In recent years, without wanting to and not to his benefit, Gilad has become fixed in the public mind as a symbol of the huge compensation paid to senior executives in the private sector, and his salary cost has attracted fierce criticism. In 2014, he earned NIS 43 million, which included a bonus of NIS 31 million from Israel Corporation controlling shareholder Idan Ofer for his role in the split of the company's holdings into two. In his seven years as Israel Corporation CEO, Gilad's salary cost totaled a huge NIS 143 million.

In this context, the "salary hi-jack" at the end of 2012 is one memorable event among several. A day before amendment 20 to the Companies Law on executive pay came into force, Israel Corporation approved a NIS 240 million options plan for its senior managers, of which NIS 25 million went to Gilad.

Israel Corporation shareholders had less to celebrate during Gilad's term. From the time of his appointment as Israel Corporation CEO in June 2007 until he left the post at the beginning of this year, Israel Corporation's share price fell 35%, while the Tel Aviv 25 Index rose 30%.

Published by Globes [online], Israel business news - www.globes-online.com - on March 6, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD CONFERNCE